Product category:
Antibodies
News Release from: Oxford BioMedica | Subject: Ova System
Edited by the Laboratorytalk Editorial
Team on 25 January 2007
Avian transgenics: Interferon Alpha in
eggs
Oxford BioMedica, Viragen , and Roslin Institute, announce the successful expression of human interferon alpha-2a in the whites of eggs laid by transgenic hens using the Ova system
This is the third therapeutic protein expressed thus far in a series of proof-of-principle studies, which aim to develop the Ova System as a novel, large-scale biomanufacturing alternative capable of cost-effectively expressing many types of therapeutic proteins Viragen holds the worldwide exclusive license to commercialise avian transgenic technology as granted by Roslin Institute
This article was originally published on Laboratorytalk on 17 Feb 2006 at 8.00am (UK)
Related stories
Avian transgenic breakthrough reported
Results are first proof-of-principle with an avian-expressed version of interferon beta; it is expected that the Ova system will be capable of cost-effectively expressing many therapeutic proteins
Avian transgenic results in scientific journal
PNAS has published an article profiling the avian transgenic (Ova) system's ability to express two therapeutic proteins in the whites of eggs of transgenic hens
Alpha interferon is a protein produced by the human immune system that is fundamental to the body's resistance to disease.
This Ova-expression study produced interferon alpha-2a, which is the active ingredient in Roferon-A (Roche), a drug approved for the treatment of certain chronic infectious diseases and cancers.
Importantly, the team has previously demonstrated that the Ova System can repeatedly target expression to the oviduct and incorporation in the egg, rather than being expressed throughout the bird, plus the characteristic of protein drug expression is able to be passed to subsequent generations.
Further reading
Manufacturing process for Parkinson's drug
First discussion of the novel production approach used for ProSavin, a LentiVector-based product, to be made at Bio 2003 this week in Washington DC.
Phase II results with Trovax are 'encouraging'
Oxford BioMedica, a gene therapy company, reported that encouraging data from five Phase II studies of Trovax, its lead cancer immunotherapy product, were presented at the annual meeting of Asco
Lentivector licensing agreement signed
Oxford BioMedica has signed a further licence agreement for its LentiVector technology with a large biopharmaceutical company
This combination of features is essential for a viable and cost-competitive manufacturing system.
Viragen has previously reported successful Ova-expression of a humanised monoclonal antibody it is developing for advanced malignant melanoma and interferon beta-1a, which is currently marketed under two competing brand names for the treatment of multiple sclerosis (MS), as Avonex (Biogen Idec) and Rebif (Merck Serono).
The project's scientific leader, Helen Sang of Scotland's Roslin Institute, commented: "With each new functional protein that we recover from transgenic hens' eggs, synthesised as a component of the egg white, we significantly advance our collective knowledge and experience.
"We have now demonstrated synthesis of three different proteins at a consistent level and will move on to characterise Ova-expressed interferon alpha to further refine and optimise the technology".
According to vice president and managing director of Viragen (Scotland) Karen Jervis, the Ova System production method differs dramatically from standard interferon manufacturing methods.
"Typically, single-subtype, recombinant alpha interferon is manufactured in bacterial or mammalian cells in bioreactors housed in complex and costly facilities.
"With the Ova System, we expect to offer large-scale manufacturing capabilities in a setting far less capital-intensive and with high levels of efficiency and quality.
"Most importantly, OVA-expressed proteins will need to adhere to extremely stringent quality standards, and we are proceeding with comprehensive internal and external studies to fully characterize the proteins we express through biochemical and functional testing.
"These data, if positive, will be pivotal in preparing both a compelling economical model and a safety/quality case for the regulatory authorities".
"I congratulate the Viragen, Roslin and Oxford BioMedica teams that all played key roles in adding another therapeutic candidate to our portfolio of Ova-expressed proteins," stated Viragen's president and CEO, Charles Rice.
"This alliance continues to pioneer advancements in the field of transgenic hen protein production, and as we gather additional supporting evidence, we will pursue strategies designed to expedite a regulatory pathway for one candidate, which we expect to ultimately lead to key commercial licenses".
Professor Alan Kingsman, Oxford BioMedica's chief executive officer, commented: "The collaboration with Viragen and the Roslin Institute to develop an effective avian transgenic system for biomanufacturing goes from strength to strength.
"This milestone further demonstrates the commercial potential of this technology.".
• Oxford BioMedica: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
